VIVUS, Inc. (VVUS)
(Delayed Data from NSDQ)
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) announced that livver drug Ocaliva has obtained approval in Canada also.
Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet
by Zacks Equity Research
Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.
Puma Soaring After Neratinib FDA Panel Win, Time to Buy?
by Zacks Equity Research
Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers.
Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data
by Zacks Equity Research
Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study
Aerie's Ophthalmic Candidate Positive in Registration Trial
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).
Regeneron Presents Positive Phase II Data on HoFH Candidate
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific Sessions.
Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) moved big last session, as its shares rose over 30% on the day.
Horizon (HZNP) Sells European Rights for Procysbi & Quinsair
by Zacks Equity Research
Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
by Zacks Equity Research
Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler.
Achaogen's Plazomicin Gets Breakthrough Therapy Designation
by Zacks Equity Research
Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae.
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio
by Zacks Equity Research
Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs
Theravance/Mylan Presents Phase III Data on COPD Candidate
by Zacks Equity Research
Theravance Biopharma, Inc. (TBPH) and partner Mylan recently announced the presentation of additional efficacy and safety data from two pivotal phase III studies evaluating its key pipeline candidate, revefenacin (TD-4208).
Ultragenyx Receives Priority Review for rhGUS from FDA
by Zacks Equity Research
The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.
BioLineRx Makes Regulatory Submission for Trial of BL-8040
by Zacks Equity Research
BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).
Merck Presents Phase II Data on Chronic Cough Candidate
by Zacks Equity Research
Merck (MRK) presented data from a phase II study on its pipeline candidate MK-7264 (formerly AF-219) at the American Thoracic Society (ATS) Annual Conference.
Roche's Arthritis Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
by Zacks Equity Research
Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.
Catalyst Pharmaceuticals Focuses on Development of Firdapse
by Zacks Equity Research
We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX) on May 22.
Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.
AstraZeneca Sells Marketing Rights to Seloken in Europe
by Zacks Equity Research
AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.
Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
by Zacks Equity Research
Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Amgen Evenity Approval Derailed on Cardiovascular Side Effect
by Zacks Equity Research
A late-stage study at Amgen, Inc. (AMGN) showed that its pipeline candidate Evenity/romosozumab led to a statistically significant superior fracture risk reduction.
Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug
by Zacks Equity Research
Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.